BioAge Labs, Inc. (BIOA)
NASDAQ:BIOA
Top Page
BioAge Labs, Inc.
(NASDAQ:BIOA)
Select Model
Select Model
Rating:51Neutral
Price Target:
$16.00
▼(-11.31% Downside)
Action:ReiteratedDate:03/25/26
BIOA scores 51 mainly due to heavy losses and significant cash burn despite early revenue growth and low leverage. Technical indicators add modest near-term caution with price below key short-term averages. Offsetting these, recent positive clinical/pipeline updates and balance-sheet strengthening via financing provide supportive optionality.
Positive Factors
Strong cash runway
A large cash balance and company guidance that funds operations through 2029 materially reduce near-term financing pressure, allowing management to advance multiple clinical programs on schedule, retain R&D investment levels and pursue strategic options without urgent capital raises.
Negative Factors
High cash burn
Sustained negative operating and free cash flow reflect heavy ongoing investment and a structural cash burn profile. Even with ample cash today, continued large negative cash flow increases the probability of future financings or spending cuts if clinical timelines or costs extend beyond current plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash runway
A large cash balance and company guidance that funds operations through 2029 materially reduce near-term financing pressure, allowing management to advance multiple clinical programs on schedule, retain R&D investment levels and pursue strategic options without urgent capital raises.
Read all positive factors
BioAge Labs, Inc. (BIOA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$789.52M
Dividend YieldN/A
Average Volume (3M)539.48K
Price to Earnings (P/E)―
Beta (1Y)1.68
Revenue GrowthN/A
EPS Growth-1.89%
CountryUS
Employees62
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.72
Shares Outstanding44,379,753
10 Day Avg. Volume430,834
30 Day Avg. Volume539,482
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.75
Price to Sales (P/S)52.85
P/FCF Ratio-5.77
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue50.78
Enterprise Value/Gross Profit51.17
Enterprise Value/Ebitda-5.55
Forecast
1Y Price Target
$47.97Price Target Upside165.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.62
Revenue Forecast (FY)$3.63M
BioAge Labs, Inc. Business Overview & Revenue Model
Company Description
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insi...
How the Company Makes Money
null...
BioAge Labs, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 8.99M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 8.99M | 0.00 | 0.00 | 0.00 |
| EBITDA | -92.78M | -68.58M | -55.90M | -39.35M |
| Net Income | -80.61M | -71.11M | -63.85M | -39.72M |
Balance Sheet | ||||
| Total Assets | 294.89M | 358.23M | 25.92M | 28.43M |
| Cash, Cash Equivalents and Short-Term Investments | 281.10M | 354.35M | 21.64M | 27.64M |
| Total Debt | 5.56M | 8.70M | 53.25M | 2.47M |
| Total Liabilities | 22.84M | 35.11M | 199.32M | 140.99M |
| Stockholders Equity | 272.05M | 323.13M | -173.40M | -112.56M |
Cash Flow | ||||
| Free Cash Flow | -82.35M | -51.89M | -37.53M | -36.28M |
| Operating Cash Flow | -81.63M | -51.52M | -37.36M | -36.18M |
| Investing Cash Flow | -95.22M | -366.00K | -266.00K | -103.00K |
| Financing Cash Flow | 11.47M | 381.20M | 34.94M | 2.50M |
BioAge Labs, Inc. Risk Analysis
BioAge Labs, Inc. disclosed 66 risk factors in its most recent earnings report. BioAge Labs, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioAge Labs, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $587.01M | 22.76 | -8.22% | ― | -10.42% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $789.52M | -4.58 | -27.86% | ― | ― | -1.89% | |
49 Neutral | $40.24M | -4.80 | -199.09% | ― | -86.05% | 24.17% | |
48 Neutral | $176.89M | -9.61 | -182.11% | ― | 0.47% | -430.88% | |
47 Neutral | $141.85M | -16.52 | -46.40% | ― | 2.82% | 60.26% |
* Healthcare Sector Average
BIOA
BioAge Labs, Inc.
17.79
14.36
418.66%
IRWD
Ironwood Pharma
3.60
2.59
256.44%
LFCR
Lifecore Biomedical
4.72
-1.00
-17.41%
SXTC
China SXT Pharmaceuticals
2.07
-396.94
-99.48%
DERM
Journey Medical Corp
5.19
-0.87
-14.36%
IXHL
Incannex Healthcare Limited Sponsored ADR
2.88
-14.22
-83.16%
BioAge Labs, Inc. Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
BioAge Highlights BGE-102 Progress and Financial Strength
Positive
Mar 24, 2026
BioAge Labs reported its full-year 2025 results and late-2025 operational milestones on March 24, 2026, highlighting strong progress for BGE-102, its oral, brain-penetrant NLRP3 inhibitor. Positive interim Phase 1 data in December 2025 and January...
Business Operations and StrategyPrivate Placements and Financing
BioAge Labs Announces Upsized Public Equity Offering
Positive
Jan 22, 2026
On January 21, 2026, BioAge Labs, Inc. priced an upsized underwritten public offering of 5,897,435 shares of common stock at $19.50 per share, for expected gross proceeds of approximately $115.0 million, and entered into an underwriting agreement ...
Business Operations and StrategyProduct-Related Announcements
BioAge Labs advances BGE-102 into ophthalmology clinical trials
Positive
Jan 20, 2026
On January 20, 2026, BioAge Labs announced an expansion of its BGE-102 development program into ophthalmology, unveiling plans to launch a Phase 1b/2a proof-of-concept clinical trial in patients with diabetic macular edema (DME) in mid-2026, with ...
Business Operations and StrategyProduct-Related Announcements
BioAge Labs advances BGE-102 with strong Phase 1 data
Positive
Jan 12, 2026
On January 12, 2026, BioAge Labs reported additional positive interim Phase 1 data for its lead candidate BGE-102, a brain-penetrant NLRP3 inhibitor in development for patients with elevated cardiovascular risk. In a multiple ascending dose cohort...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.